Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Changes in Skin Color: Clinical Perspectives01:14

Changes in Skin Color: Clinical Perspectives

The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Update on the status of women as editors in dermatology in 2024.

International journal of women's dermatology·2026
Same author

International multicenter case series of gestational dupilumab exposure in the treatment of atopic dermatitis: Maternal complications and fetal outcomes.

Journal of the American Academy of Dermatology·2025
Same author

SAIGE I: Staphylococcus aureus, Immunological, Genetic, and Environmental (SAIGE) Factors Contributing to Atopic Dermatitis and the Use of Ceramide-Containing Skincare.

Journal of drugs in dermatology : JDD·2025
Same author

SAIGE II: The Role of Staphylococcus aureus in Skin Barrier Dysfunction and the Development and Severity of Atopic Dermatitis in Young Children.

Journal of drugs in dermatology : JDD·2025
Same author

Photoprotection in Skin of Color: A Scoping Review of Barriers, Behaviors, and Pediatric Considerations.

Pediatric dermatology·2025
Same author

Systematic Review of the Epidemiology and Risk Factors for Nonsexual Transmission of Warts and Molluscum in Children.

Pediatric dermatology·2025

Related Experiment Video

Updated: Jun 18, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Pediatric psoriasis: an update.

Nanette B Silverberg1

  • 1Pediatric and Adolescent Dermatology, St. Luke's-Roosevelt Hospital Center, New York, NY, USA.

Therapeutics and Clinical Risk Management
|November 10, 2009
PubMed
Summary
This summary is machine-generated.

Pediatric psoriasis affects children under 18, often triggered by infections. Treatment varies by severity and joint involvement, prioritizing topical therapies and considering psychological impact.

Keywords:
Streptococcusautoimmunitycalcipotrieneetanerceptpsoriasistopical corticosteroids

More Related Videos

Measuring Psoriasis Severity at Home
02:28

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

Related Experiment Videos

Last Updated: Jun 18, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Measuring Psoriasis Severity at Home
02:28

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

Area of Science:

  • Dermatology
  • Pediatrics
  • Immunology

Background:

  • Pediatric psoriasis accounts for approximately 25% of all psoriasis cases.
  • It manifests in various forms, including plaque, guttate, and erythrodermic types, and can be associated with psoriatic arthritis.
  • Genetic predisposition combined with environmental factors, such as upper respiratory infections, triggers disease onset.

Purpose of the Study:

  • To review current understanding of pediatric psoriasis.
  • To outline a rational therapeutic approach for managing childhood psoriasis.

Main Methods:

  • Review of existing literature on pediatric psoriasis.
  • Analysis of therapeutic strategies based on disease severity and joint involvement.

Main Results:

  • Topical treatments like corticosteroids and calcipotriene are primary initial therapies.
  • Systemic treatments including ultraviolet light, acitretin, cyclosporine, methotrexate, and etanercept are used for more severe or complex cases.
  • Methotrexate and etanercept are effective for both skin and joint manifestations.

Conclusions:

  • Treatment selection requires careful consideration of disease severity, joint involvement, and the psychological well-being of the child.
  • A multi-faceted approach is necessary for effective pediatric psoriasis management.